Reviva (NASDAQ: RVPH) announced a regulatory update on Dec 23, 2025 following a pre-NDA meeting with the FDA about brilaroxazine for schizophrenia. The FDA provided written feedback recommending a second Phase 3 trial to generate additional efficacy and safety data prior to an NDA submission.
2 Likes
Im reasonably happy with Abilify maintena(spelling?) right now. It would take proven reductions in negative symptoms probably to get me to switch again. Or some other major benefit.
And even then, I would probably wait it out for a couple/few years.
I dont like risking unknown long term use side effects on new drugs.
2 Likes